Asia’s cosmetic and aesthetic medicine industry is expanding at a breakneck speed.
From mainland China to Southeast Asia, demand for injectables, lasers, body contouring, and “lunchtime procedures” is surging, fuelled by social media, influencer culture, medical tourism, and rapid commercialisation.
But behind the glossy marketing and growth statistics lies a sobering reality: patient harm is rising faster than safeguards.
This was the central message of a position paper released by the Asian Academy of Dermatology and Venereology (AADV) and the Asian League of Dermatological Societies (ALDS) at the MEVOS International Medical Aesthetics Congress in Guangzhou.
The paper calls for clear, enforceable red lines and harmonised training standards across Asia and Southeast Asia, placing patient safety — not profits — at the centre of aesthetic practice.
Growth Without Guardrails
China’s aesthetic medicine market alone is now worth over US$5 billion, while Southeast Asia has crossed the US$3 billion mark, with double-digit annual growth in countries such as Malaysia, Thailand, and Singapore.
New clinics open weekly. New devices launch monthly. New “certifications” appear almost overnight.
Yet, training standards, scopes of practice, and regulatory oversight remain fragmented and inconsistent across borders — and sometimes even within the same country.
The consequences are increasingly visible:
- In China, highly publicised deaths following multi-procedure “marathon” treatments have triggered regulatory crackdowns.
- In Malaysia, court cases and regulatory complaints related to unlicensed filler injections have risen sharply.
- Even in Singapore, despite strict regulations and enforcement, disciplinary actions frequently cite inadequate consent, misleading advertising, or ethical breaches.
These are not isolated incidents. They are symptoms of a system under strain.
When Commerce Overtakes Ethics
Aesthetic medicine sits at a uniquely vulnerable intersection of healthcare and consumerism. When commercial pressure dominates clinical judgement, three forms of ethical drift tend to emerge.
First is scope creep, where invasive procedures migrate from trained medical professionals to minimally trained or non-medical operators.
Second is consent erosion. Patients are often inadequately counselled about risks, alternatives, cumulative procedures, or psychological suitability, including conditions such as body dysmorphic disorder.
Third is advertising distortion, driven by influencer marketing, AI-enhanced imagery, and claims of “guaranteed” or “risk-free” results—none of which exist in real medicine.
Each erosion may seem small in isolation. Together, they undermine patient safety and the credibility of aesthetic medicine as a legitimate medical discipline.
Why Harmonisation Matters
Asia does not need a single monolithic regulator. But it urgently needs shared principles and minimum standards.
Harmonised training frameworks would allow:
- Clear definitions of who is qualified to perform injectables, lasers, and invasive procedures.
- Standardised competency-based certification before new techniques or devices are adopted.
- Comparable consent and safety protocols across borders, especially in medical tourism hubs.
Without harmonisation, unsafe practices simply migrate to the weakest regulatory environment, placing patients at risk and reputable practitioners at a disadvantage.
Drawing The Red Lines
The position paper released after MEVOS 2025 proposes three non-negotiable red lines.
- Professional red lines: Only licensed medical practitioners should perform invasive aesthetic procedures. New devices or injectables must require accredited training and peer validation—not weekend courses or brand-driven credentials.
- Regulatory red lines: Every country should move towards an aesthetic adverse-event registry, mandatory malpractice insurance, and transparent traceability of devices and injectables to combat counterfeit products.
- Ethical commerce red lines: Advertising must be truthful, balanced, and free from guarantees. Influencer-driven medical claims should be regulated with the same seriousness as pharmaceutical promotion.
These measures are not anti-growth. They are pro-sustainability.
A Shared Responsibility
Patient safety cannot rest on regulators alone. Practitioners, professional societies, industry partners, and educators all play a role.
Manufacturers must support proper training, not just product sales. Clinicians must resist the pressure to practise beyond competence.
Professional bodies must speak clearly and collectively, even when it is uncomfortable.
As stated during MEVOS 2025, professionalism is not a restraint on growth — it is the foundation that makes growth possible.
The Way Forward
Asia’s aesthetic medicine sector stands at a crossroads. One path leads to escalating harm, litigation, and public distrust. The other leads to a mature, respected discipline grounded in safety, ethics, and professional integrity.
Harmonising training standards across Southeast Asia and the wider Asian region is not merely an academic exercise. It is a moral obligation — to patients, to young doctors entering the field, and to the future of aesthetic medicine itself.
If patient safety truly comes first, then our red lines must be clear, and collectively upheld.
Dr Steven Chow is the Secretary-General of Asian Academy of Dermatology and Venereology (AADV), and President of the Asian League of Dermatological Societies (ALDS).
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.
